2025-05-12
CCRM Nordic has signed a strategic MoU with two South Korean organizations at BIO KOREA, promoting global collaboration in ATMP R&D and training.
During BIO KOREA, CCRM Nordic signed a memorandum of understanding (MoU) with two major South Korean organizations — the Regenerative Medicine Acceleration Foundation (RMAF) and the Council of Advanced Regenerative Medicine (CARM). The agreement marks a significant step forward in strengthening international cooperation in the cell and gene therapy space.
Under the new agreement, the three parties will collaborate on:
Identifying and planning international ATMP research and development (R&D) projects
Promoting commercialization of innovative regenerative medicine technologies
Creating and sharing human resource training programs
The MoU was signed by Jim Lund, CBDO of CCRM Nordic, alongside So Ra Park (President, RMAF) and Duckjoo Lee (President, CARM).
CCRM Nordic’s involvement in this agreement also reinforces its role in the CARM Global Network—a collective of leading organizations in the regenerative medicine sector. Other members include:
ISCT (International Society for Cell & Gene Therapy): A global leader in translating cell and gene therapy from research to clinical application
Biocom California: A powerhouse for life science advocacy and industry support in California
Alliance for Regenerative Medicine (ARM): The international voice of the engineered cell and gene therapy community
AusBiotech: Australia’s biotech industry body promoting global bioscience commercialization
Held annually since 2006, BIO KOREA has grown into a key international event for the bio-health industry. This year’s event brought together global experts and decision-makers in biotechnology, offering networking opportunities and insights into emerging healthcare technologies.